



SARS-COV-2 DUAL TARGET, INFLUENZA A/B AND RSV RAPID TEST

Rapid differentiation between SARS-CoV-2, Flu A/B, and RSV

Patients infected with SARS-CoV-2, Influenza A (Flu A), Influenza B (Flu B) and/or Respiratory Syncytial Virus (RSV) have overlapping symptoms, but the approaches to patient management of infections caused by the viruses are different. SARS-CoV-2, Flu A/B, and RSV is a qualitative test for the rapid triage, and patient management to identify different viruses effectively providing pathogen-specific management and targeted treatment. The combination of these tests additionally reduces costs whilst addressing the challenge of respiratory infections at the point of care, facilitating infection control and risk assessment.

Detection Method: Real-Time PCR

Result Time: < 1 hour

Sample Volume: 300µl Clinical Sample

Sample Type: Nasopharyngeal or Oropharyngeal Swab

DETECTABLE PATHOGENS
SARS-CoV-2 (E gene and N gene)
Influenza A and Influenza B
Human Respiratory Syncytial Virus



RANDOX

VIVALYTIC

Cartridge Based Testing Platform


The SARS-CoV-2 Dual Target, Influenza A/B and RSV rapid test on Vivalytic by Bosch, a point of care platform brought to the market by Randox Laboratories. The Vivalytic system is a fully automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex infectious disease testing. Each easy-to-use cartridge contains all necessary reagents, is fully-sealed to minimise risk and can be conveniently stored at room temperature.

Vivalytic Key Features:

- Cartridge based platform
- Fully-automated
- Suitable for both non-laboratory & laboratory settings
- Small footprint device
- Rapid turnaround from sample entry to results

VIVALYTIC WORKFLOW

4 Easy Steps for Optimised Workflow



To find out more email:
marketing@randox.com